CFO4Life Group’s GSK GSK Stock Holding History

CFO4Life Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,136	Closed	-$333K	–	229
2024 Q3	$333K	Buy	8,136 +1,842	+29%	+$75.4K	0.06%	148
2024 Q2	$242K	Buy	6,294 +805	+15%	+$33.9K	0.05%	167
2024 Q1	$235K	Buy	+5,489	New	+$226K	0.04%	164

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFO4Life Group's GSK Position: Q4 2024 in Review

CFO4Life Group sold out of GSK (GSK) in Q4 2024, closing a stake of 8,136 shares — an estimated $333K sold.

CFO4Life Group first reported a position in GSK in Q1 2024 and held it in 3 quarters. The position peaked at $333K in Q3 2024. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

CFO4Life Group reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
CFO4Life Group sold 8,136 GSK shares in Q4 2024, an estimated $333K.
CFO4Life Group first reported a position in GSK in Q1 2024 and held it in 3 quarters.
CFO4Life Group's GSK position peaked at $333K in Q3 2024.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on CFO4Life Group's 13F filing for Q4 2024, filed 10 Feb 2025.